IQV Earnings Date: Feb 4, 2027 (Estimated) — IQVIA Holdings Inc.
NYSE · Healthcare · Diagnostics & Research
Updated
When is IQV's next earnings date?
IQVIA Holdings Inc. (IQV) is expected to report Q4 2026 earnings on Thursday, February 4, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $3.59 on revenue of $4.53B.
How did IQV do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), IQVIA Holdings Inc. posted EPS of $3.34 versus the $3.26 estimate, a beat of 2.5%. Revenue was $4.43B against a $4.37B estimate. The stock's 1-day post-earnings move was -0.7%.
How much does IQV stock move after earnings?
IQV beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.4% (up or down) in the day after earnings.
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
🤖 AI Earnings Analysis
IQVIA delivered a solid, modest beat, with Q3 revenue up 7.3% to $4.4B and EPS rising 11.3% to $3.34. Full-year guidance of $12.80–$13.00 EPS and $17.3B–$17.5B revenue supports steady growth in healthcare research services.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | 3.26 | 3.34 | +2.45% | $4.43B | ✅ Beat | -0.75% | — | — |
| 2026-07-28 | Q2 2026 | 2.97 | 3.15 | +6.06% | $4.37B | ✅ Beat | +13.94% | +9.45% | +21.67% |
| 2026-05-05 | Q1 2026 | 2.76 | 2.90 | +5.07% | $4.15B | ✅ Beat | +9.62% | +7.84% | +13.12% |
| 2026-02-05 | Q4 2025 | 3.29 | 3.42 | +3.95% | $4.36B | ✅ Beat | -10.65% | -12.52% | -13.85% |
| 2025-10-28 | Q3 2025 | 2.86 | 3.00 | +4.90% | $4.10B | ✅ Beat | +0.32% | -1.63% | +6.66% |
| 2025-07-22 | Q2 2025 | 2.66 | 2.81 | +5.64% | $4.02B | ✅ Beat | +17.88% | +24.41% | +21.01% |
| 2025-05-06 | Q1 2025 | 2.63 | 2.70 | +2.66% | $3.83B | ✅ Beat | -4.01% | +2.51% | -2.89% |
| 2025-02-06 | Q4 2024 | 3.11 | 3.12 | +0.32% | $3.96B | ✅ Beat | +2.20% | -3.71% | -6.72% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $7.97B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Technology And Analytics Solutions | 66.9% | $5.34B | +227.2% | $1.66B | $1.55B | $1.63B | $3.45B |
| Research And Development Solutions | 33.1% | $2.64B | +16.8% | $2.12B | $2.10B | $2.26B | $4.53B |
By region
Q3 FY26 · $4.43B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 47.1% | $2.09B | +8.0% | $1.85B | $1.81B | $1.93B | $4.00B |
| EMEA | 32.0% | $1.42B | +9.3% | $1.30B | $1.22B | $1.30B | $2.66B |
| Asia Pacific | 20.9% | $924.0M | +6.2% | $807.0M | $798.0M | $870.0M | $1.71B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.